Vaccines

Promising new 96-week data shows Vir's therapy could redefine care for severe hepatitis delta, as its oncology pipeline and financial runway also advance.

Biomea Fusion launches a high-stakes 2026 plan, advancing a novel diabetes drug to restore insulin cells and an oral pill to rival obesity giants.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Recent findings of bacteria and heavy metals in baby formula have parents worried and legal experts demanding greater manufacturer accountability.

A new alliance aims to advance KFRX06, a unique Parkinson's therapy that goes beyond a single target to potentially offer a more comprehensive treatment.

Health Canada uncovers counterfeit erectile dysfunction drugs in Mississauga, warning of life-threatening dangers and a compromised supply chain.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

Aesthetics firm Evolus reports its first profitable quarter and robust growth, banking on new products and international markets to defy industry slowdowns.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

With key studies now complete, Biofrontera's light-based therapy Ameluz could soon offer a new weapon against widespread actinic keratosis and stubborn acne.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

China approves Aizhida, a novel once-daily ADHD medication. Its unique dual-action formula provides rapid and sustained symptom control, aiming to transform treatment.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

The acquisition, advised by Westcove Partners, highlights the trend of private equity-fueled consolidation aimed at enhancing clinical trial access.

Employer health plans are using 'alternative funding' to cut costs, but critics warn these schemes force patients to use risky, non-FDA approved drugs.